A Veterans Affairs (VA) Health Systems study of older male veterans found benefits of a remote model of screening that significantly improved osteoporosis screening, treatment, and adherence compared with usual care, with high patient and clinician acceptance.
Dr. John Cush RheumNow
11 months 4 weeks ago
Associations in Rheumatology (10.3.2025)
Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.
https://t.co/pnLoquR4By https://t.co/PKJuxMGrZy
Dr. John Cush RheumNow
11 months 4 weeks ago
Prospective study of 62 lupus nephritis pts rx w/ induction therapy - MMF vs IV CYC x 6 mos followed by MMF for next 6 mos. At 1 year complete renal remission (CRR) seen in 77% MMF vs 29% CYC. https://t.co/wG2Qrn1PSU https://t.co/gP8XYO4q92
Dr. John Cush RheumNow
11 months 4 weeks ago
Ethnic Minority Rheumatoid Arthritis Consortium registry study of 1315 RA pts (Dz duration 10yrs) incl 29% Blacks found Blacks in less remission(~2-fold by DAS28), more mod-hi dz activity, & frequently met active disease eligibility for RCTs. https://t.co/SfkVUB1GBz https://t.co/OwvmALHPFA
Dr. John Cush RheumNow
11 months 4 weeks ago
German survey of 124 AOSD pts - Dz duration 7 yrs (Dx delay 2 yrs), 2/3 on biologics, 84% responding, 81% inactive by CRP. MDs report 35% of pts Sx-free. More Patients report Persistent Sxs LBP (39.5%), fatigue/weakness (39%), & joint inflammation (27%). https://t.co/2FGUPrhB8H
Dr. John Cush RheumNow
11 months 4 weeks ago
Phase 3 RCT Cannabis sativa DKJ127 (VER-1) in 820 chronic low back pain (cLBP) pts. Primary endpt at wk 12 showed pain reduction of −1.9 NRS VER-01 vs −0.6 PBO (P < 0.001). Pain further decreased to −2.9 w/ 6 mos OL Rx. VER-1 was well tolerated. No addiction https://t.co/IeCV8tU2WR
Dr. John Cush RheumNow
11 months 4 weeks ago
Systematic review of obesity management meds - 56 RCTs (60,307 pts). All OMMs were better at total weight loss than PBO (P < 0.0001), >10% semaglutide & tirzepatide (both effective at NIDDM CHF). Semaglutide effective reducing pain in knee osteoarthritis https://t.co/nbdZfBDukE
Dr. John Cush RheumNow
11 months 4 weeks ago
ILD in Juvenile Dermatomyositis: Moving Toward Better Outcomes
JDM is typically recognized for its striking skin rashes, vasculopathy, and muscle inflammation. Less visible, but equally significant, is lung involvement. ILD is increasingly acknowledged as a critical driver of https://t.co/vNGWAB88Mc
A phase IV trial from Spain demonstrates that optimization of therapy by lessening biological DMARDs in rheumatoid arthritis (RA) may be feasible, with a low risk of flare.
A study of radiographic outcomes in difficult-to-treat rheumatoid arthritis (D2T RA) and poly-refractory RA (pr-RA) show a subset in whom damage is rapid and in need of more aggressive therapy.
Dr. John Cush RheumNow
11 months 4 weeks ago
FDA Approves Deuruxolitinib for use in adult patients with moderate to severe Alopecia Areata https://t.co/D6KXtDjfHL https://t.co/2WSIBWNexX
Dr. John Cush RheumNow
1 year ago
Guselkumab FDA Approved for Pediatric Psoriasis and Psoriatic Arthritis
FDA announced yesterday that guselkumab (Tremfya) is approved for use in pediatric patients moderate to severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA) in children six years and older https://t.co/GHjCgqHaJC
Dr. John Cush RheumNow
1 year ago
What is IPAF?
Idiopathic Interstitial Pneumonia with Autoimmune Features - or IPAF - describes patients with interstitial pneumonia with autoimmune features, but they don’t meet a diagnosis of a CTD.
https://t.co/ThU4pq27MU https://t.co/AOa5PALJst
Dr. John Cush RheumNow
1 year ago
🆕 ILD (Part III): clinical practice focus 🔬 Diagnostic challenges 🧑⚕️ Case-based learning 📈 Evidence & outcomes 🌍 Global perspectives ⬇️ Download & learn more: https://t.co/WhpVzAfPDD Created by @MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/4CL9mX9D6Y
